WestGene Leads mRNA Innovation at 4th mRNA Therapeutics Summit

BOSTON , Aug. 2, 2024 /– The 4th mRNA Therapeutics Summit, one of the most important conferences for the global mRNA industry, was held in Boston , USA, from July 29 to 31. More than 400 industry experts and 65 leading researchers in mRNA development gathered to discuss the latest advances and expanding applications of mRNA technology. Dr. Xiangrong Song , co-founder of Chengdu -based WestGene Biopharma, was invited to attend and share her insights on WestGene’s pioneering work in mRNA therapeutics, with a focus on the world-leading Epstein-Barr Virus (EBV)-related mRNA therapeutic cancer vaccine WGc-043.

Highlighting advances in mRNA therapy

Dr. Song presented the latest research data and technological advancements of WGc-043, the first mRNA therapeutic vaccine targeting Epstein-Barr virus (EBV)-related tumors that has achieved IND milestones in both China and the US. In her keynote presentation, Dr. Song detailed the development of WGc-043, highlighting its safety and efficacy in treating NKT cell lymphoma (NKTCL) and nasopharyngeal carcinoma (NPC). The vaccine utilizes WestGene’s innovative technologies in mRNA sequence design, novel delivery vectors, and scalable manufacturing to ensure high standards of safety and efficacy.

During the Summit , Dr. Song also discussed the broader challenges and opportunities within the mRNA industry, particularly the need to improve protein expression and delivery system efficiency while reducing production costs. She emphasized the importance of balancing efficacy and safety, a principle that has guided WestGene’s R&D efforts from the beginning. Dr. Song also highlighted WestGene’s collaborative approach, which includes licensing for access to validated candidates, co-development projects that leverage combined expertise, and technology licensing to enable partners to use WestGene’s cutting-edge solutions in their own developments, thereby accelerating innovation and therapeutic advancements.

The Summit included in-depth discussions on the latest clinical data, platform development, regulatory insights, and cutting-edge applications of mRNA therapeutics to address various indications including oncology, rare, and infectious diseases.

Dr Song concluded: “Presenting our research on this platform is very significant. mRNA technology offers new hope and options for the treatment of malignant diseases, and our studies underline the immense potential of this therapy in terms of safety and efficacy.

WestGene Biopharma remains committed to pushing the boundaries of mRNA therapeutics by leveraging its proprietary technologies and collaborative framework to deliver transformative therapies to patients around the world.

asianewstoday.com

author avatar
Md Faisal Mohamed
CATEGORIES
Share This

COMMENTS

Wordpress (0)
Disqus (0 )